When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PHR - Morgan Stanley sees 58% upside in Genmab in premarket analyst action
Phreesia Inc
Genmab A/S (NASDAQ:GMAB) initiated with Overweight rating and $30 (58% upside) price target at Morgan Stanley. Initiated with Outperform rating and $23 price target at RBC. Shares up 1% premarket.
More news on: Genmab A/S, Fulcrum Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ,